At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1 enrolled
Drug / intervention
Ruxolitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Phase II Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib and Ruxolitinib Phosphate for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Untreated Chronic Lymphocytic Leukemia. Completed, enrolled 1 participant across 1 site.
Detailed Summary
This phase II trial studies how well ruxolitinib phosphate works in treating patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Untreated Chronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMar 2017
Primary CompletionApr 2020
TodayJul 2026
First PostedFeb 3, 2017
Enrollment StartMar 8, 2017
Primary CompletionApr 29, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.4 years ago
Interventions
Ruxolitinibdrug
Given PO
Ruxolitinib Phosphatedrug
Given PO